UMEM Educational Pearls

Category: Pharmacology & Therapeutics

Title: Prothrombin Complex Concentrate Approved by FDA

Keywords: Prothrombin Complex Concentrate, warfarin, coumadin, vitamin K antagonist, anticoagulant, PCC (PubMed Search)

Posted: 5/2/2013 by Ellen Lemkin, MD, PharmD
Click here to contact Ellen Lemkin, MD, PharmD


  • Prothrombin Complex Concentrate (PCC) Kcentra™ has been approved for urgent reversal of major bleeding in patients taking vitamin K antagonists (e.g. warfarin).
  • It contains factors 2,7,9 and 10, and antithrombotic Proteins C and S.
  • Both fatal and non-fatal arterial and venous thromboembolic complications have occurred with Kcentra™. Thrombotic events occurred more frequently in the PCC group compared to plasma, although the differences were not statistically significant.
  • Volume overload occurred less frequently in the PCC group, as there is a smaller volume  administered with PCC compared to that of plasma.
  • Percentage of INR ≤ 1.3 at 30 minutes was 62% in the PCC group and 9.6% in the plasma group.

Approval of Kcentra™ may open the door for studying treatment of the bleeding patient on newer oral anticoagulants.